SecBot SecBot
8-K ·Filed Jun 22, 2026

ARVN

ARVINAS, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001628280-26-044627
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine CMO departure with replacement search underway, no immediate trading signal. Monitor for the new CMO appointment and any potential impact on clinical trial timelines or pipeline strategy. The separation agreement will be filed with the next 10-Q (quarter ending June 30, 2026) for full terms.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.14
T+0 close · Jun 22, 2026 · via day close
Latest settled
+0.25%
T+60 · $8.16
Vs SPY
−3.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 23 $8.14entry
  2. T+1 · 5mo ago −1.11%α −1.06% · $8.05
  3. T+5 · 5mo ago +1.84%α +0.83% · $8.29
  4. T+20 · 4mo ago −1.47%α −2.63% · $8.02
  5. T+60 · 2mo ago +0.25%α −3.00% · $8.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arvinas (ARVN) filed an 8-K announcing the departure of Chief Medical Officer Dr. Noah Berkowitz, effective July 3, 2026, with a search for a replacement underway. The departure is described as voluntary to pursue other opportunities, with standard severance including 9 months base salary and accelerated vesting of RSUs through May 9, 2027. This is a routine officer departure for a biotech company, the CMO role is important but not a CEO/CFO-level exit, and the filing lacks any financial data or guidance changes.

Key Facts

  • Chief Medical Officer Dr. Noah Berkowitz departing July 3, 2026
  • Departure described as voluntary to pursue other opportunities
  • Search for replacement CMO has begun
  • Severance: 9 months base salary continuation + up to 9 months health coverage
  • Accelerated vesting of RSUs that would vest on or before May 9, 2027; all other RSUs forfeited
  • Separation agreement includes standard release, confidentiality, and non-disparagement

Financial Impact

No material financial impact disclosed, severance is standard for a C-level officer departure at a ~$500M market cap biotech

Risk Factors

  • Potential clinical development disruption if CMO replacement is delayed
  • No financial or guidance data in this filing, limited read-through

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-044627
Document: 0001628280-26-044627-index-headers.html0001628280-26-044627
Document: 0001628280-26-044627-index.html0001628280-26-044627
Document: 0001628280-26-044627.txt0001628280-26-044627

Track record

21 reports on ARVN

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
  2. Nov 3, 202613d ago 8-K Bearish 5/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
  4. Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
  5. Jun 22, 202621w ago 8-K Neutral 3/10 Viewing Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
  6. Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
  7. May 12, 202626w ago 8-K Mixed 6/10 No price data
  8. May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
  9. May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
  10. May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026